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ABSTRACT
Objectives: Is it possible to live without
neurocognitive or neurological symptoms after being
infected with HIV for a very long time? These
study patients with decades-long HIV infection in
Finland were observed in this follow-up study
during three time periods: 1986–1990, in 1997 and
in 2013.
Setting: Patients from greater Helsinki area were
selected from outpatient’s unit of infectious diseases.
Participants: The study included 80 HIV patients.
Patients with heavy alcohol consumption, central
nervous system disorder or psychiatric disease were
excluded.
Primary and secondary outcome measures: The
patients underwent neurological and neuropsychological
examinations, MRI of the brain and laboratory tests,
including blood CD4 cells and plasma HIV-1 RNA.
Neuropsychological examination included several
measures: subtests of Wechsler Adult Intelligence Scale,
Wechsler Memory Scale-Revised, list learning, Stroop
and Trail-Making-B test. The Beck Depression Inventory
and Fatigue Severity Scale were also carried out. The
obtained data from the three time periods were
compared with each other.
Results: Owing to high mortality among the original
80 patients, eventually, 17 participated in all three
examinations performed between 1986 and 2013. The
time from the HIV diagnosis was 27 (23–30) years.
Blood CD4 cells at the diagnosis were 610 (29–870)
cells/mm3, and the nadir CD4 168 (4–408) cells/mm3.
The time on combined antiretroviral treatment was 13
(5–17) years. 9 patients suffered from fatigue, 5 had
polyneuropathy and 3 had lacunar cerebral infarcts.
There was a subtle increase of brain atrophy in 2
patients. Mild depressive symptoms were common.
The neuropsychological follow-up showed typical age-
related cognitive changes. No HIV-associated dementia
features were detected.
Conclusions: Polyneuropathy, fatigue and mild
depression were common, but more severe neurological
abnormalities were absent. These long-term surviving
HIV-seropositive patients, while on best-available
treatment, showed no evidence of HIV-associated
neurocognitive disorder in neuropsychological and
neuroradiological evaluations.
INTRODUCTION
HIV has been challenging mankind for more
than 30 years. The virus crosses the blood–
brain barrier (BBB) and enters the central
nervous system (CNS) at an early stage of the
infection—and never leaves it. Without treat-
ment, HIV gradually causes a variety of neuro-
logical complications including HIV-associated
neurocognitive disorder (HAND). This can
vary from a clinically asymptomatic or
mild neurocognitive disorder to severe
HIV-associated dementia (HAD). With the
development of combined antiretroviral
therapy (cART), patients with good adherence
can live a long symptom-free life, and HAD
has become rare.1 However, cART does not
eliminate the virus, and it is claimed that a
substantial portion of patients still develop
neurocognitive impairments.2–5 A low level
of cell-to-cell viral replication also occurs
during the most successful cART regimens.6 7
Even during effective cART there is a latent
reservoir of blood CD4 cells carrying the
HIV genome, which is competent for replica-
tion.8 9 Low nadir CD4 seems to predict, at
Strengths and limitations of this study
▪ The study was a very long-term, meticulous
follow-up of HIV-infected patients.
▪ The study evaluated almost half of the Finnish
HIV population during 1986–1990.
▪ A systematic neuropsychological and neuro-
logical, neuroimaging and HIV infection assess-
ment is included.
▪ The study sample is small.
▪ Survival bias.
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least partially, reversible HAND.2 Very long-term
follow-up studies on the evolution of neurocognitive
function among HIV-infected patients are lacking. To
the best of our knowledge, this is the ﬁrst study describ-
ing a group of patients followed up to as many as
30 years.
Public healthcare provides HIV treatment in Finland.
In the Helsinki area, the infectious disease unit at
Aurora Hospital has provided medical treatment for
HIV infection since 1983.10 The ﬁrst antiretroviral agent,
zidovudine, became available at Aurora Hospital in
1987. A cohort study was started in 1986, lasting 5 years,
to examine the CNS symptoms associated with HIV
infection.11 The HIV-infected patients were then reinves-
tigated in 1997.12 For this study, we re-invited the
patients in 2013, to obtain a longitudinal evaluation of
their neurocognition, and to examine the neurological
and neuroimaging ﬁndings of this group of people who
became infected with HIV-1 more than 25 years ago,
and who have been treated with optimal therapy. In
Finland, antiviral HIV medication is free for patients
through the Finnish communicable disease legislation.
METHODS
Centre and patients
This is an observational follow-up study of HIV-infected
patients who were ﬁrst enrolled in a neurological and
neuropsychological examination during 1986–1990.13 14
HIV infection and AIDS are reportable diseases in
Finland. The ﬁrst patient with an HIV infection was
diagnosed in 1983.10 The infectious disease unit at
Aurora Hospital in Helsinki takes care of HIV-infected
individuals within the greater Helsinki area. The hospital
managed a total of 98 HIV-infected patients in 1986.
The number of patients increased every year to 248 by
the year 1991. Around half of these patients (n=106)
were ﬁrst evaluated for this study during 1986–1990. The
exclusion criteria were: history of CNS disease or present
HIV-related CNS disease (not HAD), severe dementia,
marked learning disability, prominent alcohol consump-
tion (scale 4, see below) and refusal to participation.
Thus, 85 patients participated in the initial study.13 15
Later, a further ﬁve patients with previously diagnosed
psychiatric problems were excluded. Thus the study
cohort available for the follow-up totalled 80 persons.
We included those patients who were re-invited and who
agreed to participate in all three study interventions in
1986–1990,11 199712 and 2013, in this analysis.
Study interventions
During all three examination periods, detailed medical
history was taken together with information on patients’
educational background, profession and occupation.
From each patient’s medical records and previous
research records, the following data were recorded:
dates of acquisition and diagnosis of HIV infection,
history of ART, and the date of initiation of cART and
possible interruptions of the therapy. Virologically sup-
pressive therapy was deﬁned as having most plasma HIV
viral loads below the limit of detection before the year
2000 and below 50 copies/mL thereafter. Blood CD4
cells (cells/mm3) within the year of diagnosis and nadir
CD4 (the lowest blood CD4 cells value measured since
patient’s HIV diagnosis), the date of plasma HIV-1 RNA
level being below 400 copies and below 50 copies, and
any AIDS events, were recorded. Patients were further
divided into two groups depending on whether they had
used cART for more than 10 years continuously versus
patients with <10 years of cART use, or treatment inter-
ruptions. Patients were also divided into those with low
nadir CD4 (<200 cells/mm3) and those with higher
nadir CD4 values, and compared.
The diagnosis of other conditions was recorded from
the medical records and using information from the
patient: medication or diet used for diabetes mellitus,
hypertension (treated, or a history of hypertension as
systolic blood pressure ≥140 mm Hg or diastolic blood
pressure ≥90 mm Hg, or both), hypercholesterolaemia
(treated or total cholesterol level ≥5.0 mmol/L,
low-density lipoprotein (LDL) level ≥3.0 mmol/L, or
high-density lipoprotein (HDL) level <1.0 mmol/L)
and cardiovascular disease (prior diagnosis of coronary
heart disease or myocardial infarction). Diagnosis of
nephropathy or signs of protein in urine were recorded.
Any history of depression or bipolar disorder, and diag-
nosis of epilepsy or dementia, were ascertained. Patients
were also questioned about their smoking habits, and
whether they used any illegitimate drugs. Alcohol con-
sumption was estimated (scale 0–4) in the ﬁrst and last
evaluations.15 In the scale, 0=infrequent use (0–100 g
alcohol per week), 1=social drinker (101–250 g), 2=mod-
erate user (251–350 g), 3=heavy drinker (351–500 g)
and 4=alcohol abuser (>500 g). The body mass index
was calculated for all patients, to estimate their nutri-
tional status (underweight body mass index (BMI)
≤18.5 kg/m2) and obesity (BMI ≥30 kg/m2).
Neurological investigations
In 2013, all the participants completed a fatigue severity
scale (FSS) form translated into Finnish, to determine
the level of fatigue patients were experiencing.16 The
FSS has nine statements with a score range 1–7. The
patient accords a value based on how well the statement
reﬂects his condition during the previous week. A total
score ≥36 (max 63) in the FSS suggests the patient is
suffering from fatigue.16
In the year 2013 assessment, the diagnosis of polyneur-
opathy or treatment of neuropathic pain was recorded.
Each participant underwent a neurological evaluation
performed by a neurologist in all three time periods. In
2013, we used a neurostatus scoring system and the
expanded disability scale status (EDSS).17 The neurosta-
tus is divided into the domains of visual, brainstem,
pyramidal, cerebellar, sensory and bowel/bladder.
We excluded the cerebral domain, because we
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undertook neuropsychological investigations with more
detailed information. Each domain gives the patient a
functional system score (FS) where 0–1=no symptoms,
signs only; 2–3=mild symptoms and signs; 3=moderate
symptoms and signs; 4–6=severe symptoms and signs.
The domains are used to determine patients’ EDSS
together with patient’s ability to walk (ambulatory).
Both the neurostatus and EDSS are used widely to esti-
mate the functional disability of patients with multiple
sclerosis. For this study, they were adapted with the
purpose of standardising the neurological status and
making the clinical neurological examination easier to
analyse quantitatively.
Neuropsychological investigation
The neuropsychological examination included measures
of memory: the Logical Memory I of the Wechsler
Memory Scale–Revised (Wechsler’s memory scale
(WMS)–R),18 and a list learning task.19 The reasoning
was assessed using Similarities and Block Design subtests
of the Wechsler Adult Intelligence Scale (WAIS).20 The
executive functions were assessed with the Trail Making
B21 and the Interference subtask of the Stroop colour
word test.22 The speed of performance was measured
with the Digit Symbol subtest of the WAIS and a naming
subtest of the Stroop colour word test. Depression was
evaluated with a short form of the Beck Depression
Inventory (BDI).23 All participants were investigated
with the same neuropsychological tests in all three study
periods.
Neuroradiological investigation
MRI was performed on 16 patients both in 1997 and
2013. The ﬁrst brain MRI was performed using a 1.5 T
unit (Siemens, Vision). The MRI protocol included con-
ventional T2, ﬂuid-attenuated inversion recovery, T2
coronal and T1 multiplanar reconstruction (MPR) sagit-
tal images. The second imaging, in 2013, was performed
using a 3 T unit (Philips, Achieva). The MRI protocol
also included T2*, susceptibility weighted imaging
(SWI) and diffusion weighted imaging (DWI) axial
sequences.
All brain abnormalities including infarcts and bleed-
ings were recorded. White matter hyperintensities
(WMHIs) were classiﬁed as periventricular WMHIs or
deep WMHIs, and graded 0 through 3. The severity of
white matter lesions (WMLs) was rated with the Fazekas
scale.24 The bicaudate ratios and the width on the third
ventricle were measured to estimate brain atrophy.
Laboratory investigations
Apart from the HIV laboratory work up aforementioned,
the following laboratory assessments were made: a com-
plete blood count, liver function (aspartate aminotrans-
ferase, alanine aminotransferase, alkaline phosphatase,
total bilirubin), kidney function (creatinine, protein in
urine), plasma glucose and lipids (total cholesterol, high
HDL, LDL and triglycerides), viral hepatitis serology
(hepatitis B antigens (HBsAg, HBcAb), hepatitis C
antigen (HCVAb), syphilis serology (treponema palli-
dum haemagglutination and cardiolipin antigen
(Venereal Disease Research Laboratory) tests).
A current cerebrospinal ﬂuid (CSF) sample was avail-
able for routine analysis from nine patients.
Statistics
Statistical analyses were computed using IBM statistics
software SPSS V.22.00. Neuropsychological parameters
were analysed with multivariate analyses of variance
(Manovas) controlling the effect of age in all analyses.
In the analysis of other parameters, simple parametric
and non-parametric tests along with simple descriptive
statistics, were used, as appropriate.
All patients gave their written informed consent to
participate in the study.
RESULTS
After exclusions, the original study group consisted of 80
patients during the period 1986–1990. By the 1997
evaluation, 47 patients had passed away, 7 had been lost
to follow-up and 3 patients refused the follow-up evalu-
ation; consequently, 23 patients were evaluated in 1997.
Between 1997 and the current evaluation, a further ﬁve
patients had passed away, two from AIDS-related compli-
cations after 1997, and three from non-AIDS-related
causes four or more years after 1997. For the latest evalu-
ation, we were able to contact 18 HIV-infected patients
to participate in the neurological, neuropsychological,
radiological and laboratory work up. The patients were
all men. They had a sexually acquired HIV infection, 16
through homosexual or bisexual contact and two
through heterosexual contacts. All 18 patients gave their
consent to participate in the study. One was too ill to
participate in extended investigations and was only
visited by the neurologists. His EDSS was 9.0. During the
intervention in 2013, he died. No signs of
HIV-associated brain damage were observed in post
mortem autopsy. The results of the remaining 17
patients are reported here.
The demographic and clinical characteristics are pre-
sented in table 1. Of the 17 patients, 11 (65%) had low
nadir CD4 of <200 cells/mm3, and 3 (18%) had had
AIDS events (one patient with oesophageal candida, one
with pneumocystis pneumonia, and one with Kaposi’s
sarcoma and pneumocystis pneumonia. The patient with
two AIDS illnesses had convulsions twice while receiving
treatment for pneumocystis pneumonia). There were no
elite controllers of HIV-1 viraemia among the patients,
whose median of the maximal HIV-1 viral load in
plasma was 145 000 copies/mL (range 10 900–9 360 000
copies/mL). The median year of ﬁrst starting ART was
1992 (range 1989–2002). Nine patients had undergone
continuously virologically suppressive ART for 10 years
or longer. The remaining eight patients had had inter-
ruptions of suppressive ART or had taken continuously
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suppressive ART for <10 years. The current antiretroviral
combinations are shown in table 2.
Depression was diagnosed and treated in 4 (24%)
patients. In the results of BDI between the three study
time periods no signiﬁcant changes appeared: BDI
mean scores were 4.65, 5.53 and 5.00, respectively
(Friedman, χ2=0.5, p=0.779) indicating mild depressive
symptoms. The BDI result did not vary between the
groups of low nadir CD4 or patients with cART for more
than 10 years. Hypertension was medicated and treated
in 5 (29%) patients. Diabetes was diagnosed in two
patients. Nephropathy was diagnosed in two patients,
one caused by diabetes and the other by prostatic hyper-
plasia, while two other patients had protein in urine.
Dyslipidaemia was diagnosed in 11 (65%) patients. One
patient was underweight (BMI 17.5 kg/m2) and one
obese (BMI 34.3 kg/m2). Alcohol consumption had
been moderate and was reduced signiﬁcantly between
the ﬁrst and last examination (mean score±SD: 0.82
±.0.64 vs 0.35±0.79, Wilcoxon, Z=−2.3, p=0.021).
Tobacco smoking was noted in 7 (41%) patients. One
patient admitted to occasionally using marihuana. None
of the patients used intravenous or other illegitimate
drugs.
Four of the patients had a diagnosis of neuropathy.
On clinical neurological examination, an additional
patient had signs of neuropathy (Sensory FS 3.0–4.0).
Four of ﬁve patients with neuropathy had been treated
with deoxynucleosides, four with stavudine from 3 to
10 years and 3 with didanosine from 3 to 4.5 years. Only
one patient with neuropathy had not been treated with
deoxynucleosides. Altogether, six patients had EDSS
between 3.0 and 4.0 (mean=3.4), indicating moderate
disability. In ﬁve, this was due to neuropathy. One
patient had mild extrapyramidal ﬁndings and bladder
dysfunction, which increased his EDSS. None of the
patients had prominent loss of vision, cerebellar ataxia,
marked pyramidal symptoms or other clear signs of CNS
abnormalities. They were all fully ambulatory. Most of
the patients (16) had intact sensation of smell.
The neuropsychological examination showed a mild
decline in raw scores, particularly between the second
and last examination, but no signiﬁcant changes were
found when age was controlled for in statistical analyses
(repeated measures Mancova) (table 3). No effect on
cognition was traced on patients during the follow-up
whether they were on cART for at least 10 years continu-
ously, for <10 years, had an interruption of cART, or low
nadir CD4.
The neuroradiological follow-up showed only a
minimal age-related increase in atrophic changes. The
mean bicaudate ratio was 0.12 in 1997 and 0.13 in 2013,
and the mean width of the third ventricle was 0.57 and
0.68 cm, respectively. Two of the patients showed a
slightly more prominent increase in atrophy. Four
patients had new WMHIs. Three of the patients had new
lacunar infarcts, one of which had already been seen in
1997. One of the three patients also had microhaemor-
rhages not seen in 1997. One of these patents with
stroke was the eldest (75 years) of our study group and
had some decline in neuropsychological performance.
However, the other patients with mild brain atrophy or
stroke seen in the MRI had no detectable decline in cog-
nitive performance.
A CSF sample was taken from nine patients in 2013.
HIV-1 in CSF was below 20 copies/mL in eight patients.
The ampliﬁcation test failed technically on one sample.
About half of the patients had elevated protein or
immunoglobulin in CSF (table 4). The leucocyte count
and immunoglobulin–albumin ratio were within normal
range in most patients studied (table 4).
Five patients had positive HBcAb, indicating an earlier
hepatitis B infection. None, however, were HBsAg posi-
tive; hence none of the patients were chronically
Table 1 Demographic and clinical characteristics of the
study population
Characteristic (unit) Median Range
Age (years) 57.0 46–75
Education (years) 12.0 9–23
HIV infection* (years) n=16 28 23–31
HIV diagnosis† (years) 27 23–30
CD4 at diagnosis‡ (cells/mm3) n=15 610 29–870
nadir CD4 (cells/mm3) 168 4–408
ARV (years) 19 9–24
cART (years) 13 5–17
BMI (kg/m2) 23.4 17.5–34.3
EDSS 2.0 1.0–4.0
FSS 32 9–63
The number of patients (n) is 17 unless mentioned otherwise.
*Patients’ own estimations about time from HIV infection.
†Time from HIV diagnosis.
‡The first blood CD4 cells, within a year of the diagnosis.
ARV, use of any antiretroviral therapy; BMI, body mass index;
cART, antiretroviral therapy consisting of at least 3 agents; EDSS,
expanded disability scale status; FSS, fatigue status scale.
Table 2 Current cART regimens of 17 HIV-infected
patients
cART regime
Number of
patients Remarks
2NRTI+boosted PI 7
2NRTI+NNRTI 3
2NRTI+INSTI 1
1NRTI+boosted PI
+INSTI
1 Intolerance to NRTIs
1NRTI+boosted PI
+NNRTI
1 1 class ART resistance
NNRTI+boosted PI
+INSTI
2 2 class ART resistance
in both patients
2NRTI+boosted PI
+NNRTI+INSTI
2 3 class ART resistance
in both patients
2NRTI, two nucleoside reverse transcriptase inhibitors; ART,
antiretroviral therapy; INSTI, integrase strand transfer inhibitor;
NNRTI, non-NRTI; PI, protease inhibitor.
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infected with hepatitis B. One patient had a positive
syphilis serology with history, and a serological follow-up
of an adequate treatment of syphilis. All patients were
HCVAb negative.
DISCUSSION
This study shows, for the ﬁrst time, that Finnish
HIV-1-infected patients who receive adequate anti-HIV
therapy may preserve their neurological and neurocog-
nitive function well despite of a history of HIV infection
of up to 30 years.
All cART-medication regimes are reducing the risk of
the severest forms of HAND. Nevertheless, milder forms
have been reported as becoming more common.25 26
HIV is transported from the periphery through the BBB
in the CNS with both monocytes and CD4 cells.27 28 In
the CNS, the monocytes transfer HIV into macrophages
and microglial cells, both of which can produce HIV
virions. HIV infection may either be haematogenous or
‘autonomous’, when viral replication takes place in the
CNS, or a mixture of both.27 Astrocytes also become
infected with HIV, but HIV does not replicate in astro-
cytes. The infected macrophages and microglial cells
elicit an inﬂammatory reaction, which leads to recruit-
ment of more infected immune cells in the brain.28
Further astrocytes contribute to the damage of the brain
by producing neurotoxic factors, such as glutamate.26
The only known therapy reducing CNS damage by HIV
is ART. Even a monotherapy with zidovudine decreases
the amount of inﬂammatory reaction in the CSF.29 The
modern cART regimens inhibit the replication of HIV
almost completely in the periphery. These regimens
have been shown to reduce the HIV load to an undetect-
able level in the CNS in most patients.30 The inﬂamma-
tion markers in the CSF may persist at an elevated level
even after 4 years of virologically successful cART.31 Our
results indicate that cognitive function can be preserved
in HIV-infected patients for a couple of decades, despite
the probable inﬂammatory activity in the CNS.
Some HIV-infected patients have been described as
having a viral escape of HIV in the CNS in spite of suc-
cessful cART in the periphery.32 The phenomenon is
fairly rare, affecting a minority of patients receiving suc-
cessful cART. Taking into account the laboratory investi-
gations, clinical examinations and brain MRI
performed, it appears our cohort did not include such
patients. The factors contributing to the good cognitive
state in our patients probably include long-term ART,
which, on average, had been 19 years, of which, on
average, 13 years had been on cART. Second, the lack of
drug abuse, which is perhaps synergistic with HIV to
cause HAND. The CHARTER study recruited 1555
HIV-infected patients across the USA and found that
52% had at least mild neuropsychological impairment.2
In that study sample, about one-third (28%) were using
some recreational drug. Third, the good neurocognitive
outcome is caused most likely by biological variation in
our patients’ properties to resist HIV infection, and their
willingness to start ART. Fourth, lack of hepatitis C infec-
tion may contribute to the good neurocognitive
outcome of our patients.33 34
Table 3 Cognitive functioning of the 17 HIV-infected patients at three follow-up examinations
Year of examination
Follow-up time/years
1986–1990
0
1997
7–11
2013
23–27 Manova/Anova* Effect size
Mean (SD)† Mean (SD) Mean (SD) F p Value η2
Cognitive function
Memory 1.920 0.172 0.390
WMS logical memory 11.9 (2.1) 13.8 (2.5) 10.0 (2.6) – – –
List learning 57.9 (6.2) 61.9 (5.4) 57.3 (7.4) – – –
Reasoning 0.895 0.496 0.230
WAIS similarities 21.9 (1.7) 21.3 (1.8) 20.9 (2.0) – – –
WAIS block design 40.9 (6.5) 41.5 (5.3) 37.9 (6.1) – – –
Executive function 0.330 0.953 0.099
Trail-making B 85.3 (21.5) 99.4 (29.8) 105.9 (27.2) – – –
Stroop interference test (time) 104.2 (24.8) 99.2 (22.6) 115.5 (34.8) – – –
Speed of performance 1.221 0.353 0.289
WAIS digit symbol 59.3 (11.0) 55.4 (16.8) 48.9 (12.7) – – –
Stroop naming (time) 55.4 (11.6) 57.0 (11.4) 67.4 (15.7) – – –
*Age is used as a covariate.
†Raw scores.
WAIS, Wechsler Adult Intelligence Scale.
Table 4 Cerebrospinal fluid of nine patients in 2013
Median Range
Over upper
limit of normal
Protein, mg/L 451 268–675 5/9
Leucocytes 1 0–4 1/9
Immunoglobulin 31 10–82 4/9
Ig index 0.60 0.55–0.70 4/9
Ig/Alb index 0.16 0.09–0.22 1/9
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The only signiﬁcant neurological impairment detected
in our study population was peripheral neuropathy.
Apart from one patient with extrapyramidal signs, no
signs of other CNS impairment were found on clinical
examination. The earlier ART probably contributed to
the development of neuropathy, because many patients
had used deoxynucleoside analogues, which are known
to cause toxic neuropathy, as a part of their ART.
A great proportion of our patients had diseases that
constitute risks for cerebrovascular diseases. However, the
only risk factor that was signiﬁcantly higher than in the
general population of Finland, was, expectedly, the preva-
lence of hypercholesterolaemia. This is a well-known side
effect of cART, especially the group of protease inhibi-
tors.35 36 Diabetes, hypertension and hypercholesterol-
aemia were treated appropriately, which also decreased
the risks for neurological and neurocognitive defects.
Although the neuropsychological raw scores declined,
especially between the second and last examination, no
signiﬁcant differences were found when the effect of age
was controlled for. Thus, the decline may be explained
by the normal ageing effects, as the follow-up period was
almost 30 years, with the patients being, on average,
57 years of age at the time of the last examination.
In the MRI, the signs of silent strokes support the
research, which shows an increase of the incidence of
stroke in the ageing HIV population.37 38 Only two of
our patients had developed brain tissue atrophy that was
more signiﬁcant than in generally healthy ageing men
(annually 0.1–0.3%).39 40
The limitations of the study include the survival beneﬁt
and small sample size. It may well be that our population
of survivors from the era when anti-HIV medication was
not available or did not give long-term suppression of
HIV-1 replication represent a subgroup of HIV-infected
patients who tolerate the infection better than men on
average. On the other hand, the recruited study group
represents almost a half of HIV-infected patients treated
in Aurora Hospital during the 1980s.
In conclusion our results give credence to the view
that HIV-1-infected patients may well preserve their neu-
rocognitive function when cART is started in time and
delivered well, and when other conditions that could
threaten the brain are treated appropriately. Apart from
polyneuropathy, no signiﬁcant neurological or neuro-
psychological trend of impairment was found in our
study group. It is possible that the prevalence of neuro-
cognitive impairment in the CHARTER study may not
apply to all HIV-1-infected patients.
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